The most common adverse effect of<unk>  is the development of mild or moderate rash (13%). Severe or life-threatening skin reactions have been observed in 1.5% of patients, including Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity.<unk>  may cause severe or life-threatening liver toxicity, usually emerging in the first six weeks of treatment. In 2000, the U.S. Food and Drug Administration issued a black box warning on<unk> , warning that it could cause life-threatening liver toxicity and skin reactions. Unacceptably high risk of serious liver symptoms in certain patient groups (women with CD4 count >250 and men >400) has led the U.S. DHHS to recommend the restriction of<unk>  use to those at lower risk, unless the benefit to the patient clearly outweighs the risk; although in the 2NN study which found these CD4 limits, the effect was seen only in patients recruited from Thailand. More recent studies on the use of<unk>  in people with higher CD4 cell counts have come to the following conclusion: Treatment-experienced patients who start<unk> -based combination therapy with low pre–ART and high current CD4 cell counts and an undetectable VL have a similar likelihood for discontinuing<unk>  therapy because of hypersensitivity reactions (HSRs), compared with treatment-naive patients with low CD4 cell counts. This suggests that<unk> -based combination therapy may be safely initiated in such patients. However, in similar patients with a detectable VL, it is prudent to continue to adhere to current CD4 cell count thresholds. The U.S. Public Health Service Task Force advocates caution in the use of<unk>  in pregnancy due to toxicity issues, which may be exacerbated during pregnancy. Cases of immune reconstitution syndrome and fat redistribution have also been observed with this drug. The U.S. Food and Drug Administration recommends stopping<unk>  if a person experiences: * sign and symptoms of liver issues such as hepatitis * increased transaminases in addition to rash or systemic symptoms * formation of rash with systemic symptoms * severe skin or hypersensitivity reactions Additionally, the U.S. FDA recommends close monitoring during the first 6 weeks of therapy for the above symptoms as there is high risk during this time. Continued monitoring is recommended for up to the first 18 weeks of treatment. If a patient experiences hepatitis plus rash or other systemic symptoms, or severe hypersensitivity or skin rash,<unk>  should not be restarted.
Nevirapine
Saquinavir
Fostemsavir
Coronavir
Letermovir
Entecavir
Sorivudine
Maribavir